tbuckley/cabot-search huggingface dataset:
The Transplantation and Replacement of Thoracic Organs: The Present Status of Biological and Mechanical Replacement of the Heart and Lungs
Authors: D. K. C. Cooper, Leslie W. Miller, G. Alexander Patterson
Journal: Annals of Internal Medicine (1991)

It gives us great pleasure to contribute a short introduction outstanding book. This comprehensive work provides an to this important volume. immense fund of information, and will be an invaluable The transplantation of thoracic organs - heart, heart source of knowledge to physicians, surgeons, and scientists lung, lung - is a field of surgery that is expanding annually. for many years to come. The use of mechanical assist devices and artificial hearts to support patients awaiting transplantation is also developing rapidly, and further advances in this field may eventually April 1990 Christiaan Barnard lead to a totally implantable device that will function Cape Town, South Africa successfully for many years. It is therefore timely that such a volume as this should be made available to those who wish to be brought up-to date with the current state of knowledge in these related fields. The editors have done us all a great service in bringing together experts in every aspect of heart and Nazih Zuhdi lung transplantation and replacement to contribute to this Oklahoma City, USA Xl Preface The fields of the transplantation and replacement of thoracic Refinements in bioengineering have enabled mechanical organs have expanded immensely since the first human assist devices and the total artificial heart to support patients to-human heart transplant was performed in 1967. This successfully until a suitable donor becomes available.
Atlas der Hautkrankheiten.
Authors: Isidor von Neumann
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antiarrhythmic Effects of Increasing the Daily Intake of Magnesium and Potassium in Patients With Frequent Ventricular Arrhythmias fn1fn1This study was supported by Trommsdorff GmbH and Company, Alsdorf, Germany and Hexal AG, Holzkirchen, Germany.
Authors: Manfred Zehender, Thomas Meinertz, Thomas Faber, Anton Caspary, Andreas Jeron, Katja Bremm, Hanjörg Just
Journal: Journal of the American College of Cardiology (1997)
Abstract 13545: MicroRNA-33b Knock-in Mice for an Intron of Sterol Regulatory Element-Binding Factor 1 (Srebf1) Exhibit Reduced HDL-C in vivo
Authors: Takahiro Horie, Tomohiro Nishino, Osamu Baba, Yasuhide Kuwabara, Tetsushi Nakao, Masataka Nishiga, Shunsuke Usami, Masayasu Izuhara, Fumiko Nakazeki, Yuya Ide, Satoshi Koyama, Masayuki Yokode, Toru Kita, Takeshi Kimura, Koh Ono
Journal: Circulation (2014)

Background: MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports, including ours, indicated that miR-33 (miR-33a) located within the intron of sterol regulatory element-binding protein (SREBP) 2 controls cholesterol homeostasis and can be a possible therapeutic target for treating atherosclerosis. Primates, but not rodents, express a second miR-33 gene (miR-33b) from an intron of SREBF1. To address miR-33b function in vivo, we developed humanized mice, in which a miR-33b transgene is inserted within a Srebf1 intron. Methods and Results: The human miR-33b sequence was introduced into intron 16 of mouse Srebf1 by conventional gene targeting methods, because miR-33b is located in intron 16 of human SREBF1 and there are high homologies in exons 16 and 17 between human and mouse. We successfully established miR-33b knock-in (KI) mice with C57BL/6 background and this miR-33b KI strategy did not alter Srebf1 intron 16 splicing, which was confirmed by RT-PCR and sequencing. The expression of miR-33b in miR-33b KI hetero mice were almost half of those in miR-33b KI homo mice. An LXR agonist T0901317, which induces Srebf1 expression, enhanced miR-33b expression in primary hepatocytes and the liver of miR-33 KI homo mice. The protein levels of known miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced compared with those in wild-type mice. Peritoneal macrophages from the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Serum HDL-C levels were reduced by almost 35% even in miR-33b KI hetero mice compared with wild-type mice. HPLC elution analysis showed that the decreased HDL levels were mainly composed of very large-, large-, medium sized HDL, which was compatible with the previous results of miR-33a deficient mice. Conclusions: miR-33b KI mice for an intron of Srebf1 showed reduced HDL-C levels. These results indicate that miR-33b can be a potential target for raising HDL-C in humans and may account for lower HDL-C levels in humans than those in mice. These mice will aid in elucidating the roles of miR-33s in different disease models and in screening of the drugs that can alter miR-33a and miR-33b levels and activities.
Care of older people: Promoting health and function in an ageing population
Authors: G. R Andrews
Journal: BMJ (2001)

This is the second in a series of four articles 

To ensure the health and wellbeing of the growing numbers and proportion of older people during the opening decades of the new century will require greater effort in health promotion and disease prevention in old age. This article reviews evidence of the effectiveness of strategies for promoting health and function, particularly the benefits of exercise in old age.

#### Summary points

Evidence points to an overall decline in the prevalence of disability in successive cohorts of older people

For maintaining health and function in ageing, the social, mental, economic, and environmental determinants of health in old age must be taken into account

The health benefits of exercise may often relate to psychosocial as well as direct health gains

Most of the health benefits can be gained from regular physical activity of moderate intensity

Health and wellbeing at older ages is modifiable, and substantial gains could be made by promoting health and fitness throughout life

The extent to which age, chronic disease, and disability are interrelated—and the extent to which population ageing is inevitably accompanied by increased prevalence of chronic disease and disability among older people—remains controversial. In the early 1980s Fries argued that there would be an upper limit to life expectancy but that the onset of morbidity (illness and incapacity) could ultimately be postponed until about the age of 85 and there would thus be a “compression of morbidity.”1 The period of healthy life would thus be extended, he postulated, and the period of morbidity could potentially be “compressed” into the brief interlude …
Abstract 12591: Impact of Aldosterone Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism
Authors: Takeshi Matsumoto, Yukihito Higashi, Nozomu Oda, Akimichi Iwamoto, Yumiko Iwamoto, Masato Kajikawa, Tatsuya Maruhashi, Ayumu Nakashima, Kensuke Noma, Yasuki Kihara
Journal: Circulation (2014)

Background: Hypertension is associated with endothelial dysfunction and activated Rho-associated kinases (ROCKs) activity. Primary aldosteronism (PA) is a most common cause of secondary hypertension. Recent studies have shown that risk of cardiovascular events is higher in patients with PA than in patients with essential hypertension (EH). However, there is little information on the relationship between subtype of PA and the grade of atherosclerosis. The purpose of this study was to evaluate the vascular function and ROCK activity in patients with PA. Methods: Vascular function, including flow-mediated vasodilation (FMD) and nitroglycerin-induced vasodilation, and ROCK activity in peripheral leukocytes were evaluated in 21 patients with aldosterone producing adenoma (APA) group (50.7±14.3 years, 9 males), 23 patients with idiopathic hyperaldosteronism (IHA) group (55.8±9.9 years, 12 males), and 33 age-, gender-, and blood pressure-matched EH group (54.9 ± 10.7 years, 18 males). Results: FMD was significantly lower in the APA group than in the IHA group and EH group (3.2±2.0% vs. 4.6±2.3% and 4.4±2.2%, P&lt;0.05, respectively), whereas there was no significant difference in FMD between the IHA group and EH group. There was no significant difference in the response of nitroglycerine in three groups. ROCK activity was significantly higher in the APA group than in the IHA group and EH group (1.29±0.57 vs. 1.00±0.46 and 0.81±0.36, P&lt;0.05 and P&lt;0.001, respectively), whereas there was no significant difference in ROCK activity between the IHA group and EH group. FMD correlated with age (r=-0.31, P&lt;0.01), brachial arterial diameter (r=-0.44, P&lt;0.01), plasma aldosterone concentration (PAC) (r=-0.35, P&lt;0.01) and plasma renin activity ratio (ARR) (r=-0.34, P&lt;0.01). ROCK activity correlated with age (r=-0.24, P=0.04), PAC (r=0.33, P&lt;0.01) and ARR (r=0.46, P&lt;0.01). Conclusions: APA was associated with both endothelial dysfunction and increased ROCK activity compared with those in IHA and EH. These findings suggest that APA may have a higher risk of future cardiovascular events.
Abstract P6-05-03: CD4 Th1 cytokines and HER-2/HER-3 blockade induces tumor senescence in breast cancer
Authors: Cinthia Rosemblit, Brian J Czerniecki
Journal: Cancer Research (2015)

Abstract Background: HER-2 a molecular oncodriver in breast tumorigenesis is over expressed in 25% of human breast cancers, and its expression correlates with enhanced tumor aggressiveness. While targeted therapies have improved outcomes many patients become resistant or recur. We have recently established a progressive loss in anti-HER-2 CD4 Th1 responses during disease progression and is associated with outcomes. The pleiotropic Th1 cytokines IFN-γ and TNF-α have diverse effects on tumor epithelial cells. In this study we sought to determine whether these Th1 cytokines induce senescence of HER-2 expressing breast cancer cells and assess the impact of IFN-γ and TNF-α with simultaneous HER-2 and HER-3 blockade. Results: All breast cancer cell lines tested express IFN-γ and TNF-α receptors measured by western blot analysis. The high and intermediate HER-2 expressing cells are sensitive to tumor senescence induction when treated with combinations of IFN-γ and TNF-α in a dose dependent manner. Low HER-2 expressing cells were less sensitive to senescence induction as measured by positive β-galactosidase activity and the expression of p15INK4b and p16INK4a by western blot. Addition of IFN-γ and TNF-α treatment to HER-2-depleted cells by RNAi resulted in an increase senescent phenotype and was increased further when the cells were double HER-2- and HER-3-depleted. To determine whether CD4 Th1 mediated effects on high HER-2 human breast cancer cell lines, we co-cultured increasing number of HER-2 antigen-primed CD4+ T cells with high HER-2 human breast cancer cells in a transwell cell culture system. This resulted in a dose-dependent senescence of breast cancer cells compared with CD4+ T cells primed either with immature dendritic cells (DC) or mature DC plus irrelevant (Class II BRAF) peptide. In addition, SK-BR-3 breast cancer cells incubated with the supernatant of the CD4+ T cells-immature DC or mature DC co-culture demonstrated similar results. CD4+ Th1-elaborated cytokines IFN-γ and TNF-α in the supernatants were confirmed using ELISA. Blocking antibodies against IFN-γ and TNF-α demonstrated reduced senescence induction. Conclusions: Our results establish a role for IFN-γ and TNF-α in inducing tumor senescence in breast cancer. An effective CD4 Th1 responses combined with HER-2 and HER-3 blockade can significantly drive tumor senescence in breast cancer that can be explored as treatment to effectively eliminate residual breast cancer cells and prevent recurrence. Citation Format: Cinthia Rosemblit, Brian J Czerniecki. CD4 Th1 cytokines and HER-2/HER-3 blockade induces tumor senescence in breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-05-03.
Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age
Authors: C. Flohr, K. England, S. Radulovic, W.H.I. McLean, L.E. Campbell, J. Barker, M. Perkin, G. Lack
Journal: British Journal of Dermatology (2010)

Filaggrin loss-of-function (FLG) mutations are associated with eczema and skin barrier impairment, but it is unclear whether skin barrier impairment precedes phenotypic eczema in FLG mutation carriers.
Abstract 15345: Prevalence of Abnormal Preparticipation Screening H&amp;Ps in Collegiate Athletes as Compared to Focused Screening Echocardiography
Authors: Daniel Modaff, Sheila Hegde, Dennis Helwig, Nancy Bell, Peter Rahko
Journal: Circulation (2014)

Introduction: For all competitive athletes, the American Heart Association preparticipation screening (AHA PPS) guidelines recommend a 12 element focused history and physical. Evaluation of an abnormal PPS finding is left to the clinician’s discretion. The correlation between an abnormal PPS finding and structural heart disease is not well documented. A murmur on physical exam is classically used as a tool to identify a multitude of structural heart abnormalities. We propose that the current AHA PPS and specifically, a murmur detected on exam, correlate poorly with true echocardiographic abnormalities in the collegiate athlete population. Methods: A PPS modeled after the AHA guidelines was conducted on all incoming athletes at a single university from 2007 to 2013. All athletes independently underwent a focused screening echo the same day of the exam. PPS examiners were blinded to results of the screening echoes. Data from both screening exams were compared. We report the prevalence of abnormal H&amp;P findings and its relation to structural abnormalities found on focused echo screening. Results: There were 2472 athletes screened. At least one positive PPS element was noted in 655 (26.5%) athletes. Of this group, 24 (3.7%) had an abnormal focused echo. The PPS was normal in 1817 (73.5%) athletes but an abnormal echo was found in 19 of these athletes, indicating 44.2% of all abnormal echoes (N=43) had a negative PPS. Of the athletes with abnormal echo findings, 23 had structural abnormalities classically associated with a murmur. Only four of these athletes had an actual murmur on exam. In total, a murmur was detected in 36 athletes. By echocardiography, 25 (69.4%) had no structural abnormalities, thereby rendering the murmur benign. A murmur consistent with a minor structural abnormality was found in 7 (19.4%) athletes, and a murmur consistent with a significant structural abnormality was found in 4 (11.1%) athletes. Conclusions: The AHA PPS and specifically, a murmur on exam, do not reliably detect the presence of structural heart disease. An abnormal PPS is rarely associated with structural heart disease and an immediate focused echo can rapidly determine this and eliminate the need for further cardiac evaluation.
Nous devons mourir, nous et tout ce qui est nôtre
Authors: M. Therese Southgate
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission
Authors: S. Coimbra, H. Oliveira, M.J. Neuparth, J.B. Proença, A. Figueiredo, P. Rocha-Pereira, A. Santos-Silva
Journal: British Journal of Dermatology (2015)

Journal Article Systemic inflammation and proinflammatory interleukin‐17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission Get access S. Coimbra, S. Coimbra UCIBIO@REQUIMTE Departamento de Ciências Biológicas Laboratório de Bioquímica Faculdade de Farmácia (FFUP) Universidade do Porto R. Jorge Viterbo Ferreira 228 4050‐313 Porto PortugalCESPU Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde Gandra‐PRD Portugal Correspondence: Susana Coimbra and Alice Santos‐Silva. E‐mails: ssn.coimbra@gmail.com; assilva@ff.up.pt Search for other works by this author on: Oxford Academic Google Scholar H. Oliveira, H. Oliveira Serviço de Dermatologia Centro Hospitalar e Universitário de Coimbra Universidade de Coimbra Coimbra Portugal Search for other works by this author on: Oxford Academic Google Scholar M.J. Neuparth, M.J. Neuparth CESPU Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde Gandra‐PRD Portugal Search for other works by this author on: Oxford Academic Google Scholar J.B. Proença, J.B. Proença CESPU Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde Gandra‐PRD Portugal Search for other works by this author on: Oxford Academic Google Scholar A. Figueiredo, A. Figueiredo Serviço de Dermatologia Centro Hospitalar e Universitário de Coimbra Universidade de Coimbra Coimbra Portugal Search for other works by this author on: Oxford Academic Google Scholar P. Rocha‐Pereira, P. Rocha‐Pereira Centro de Investigação em Ciências da Saúde (CICS) Universidade da Beira Interior Covilhã Portugal Search for other works by this author on: Oxford Academic Google Scholar A. Santos‐Silva A. Santos‐Silva UCIBIO@REQUIMTE Departamento de Ciências Biológicas Laboratório de Bioquímica Faculdade de Farmácia (FFUP) Universidade do Porto R. Jorge Viterbo Ferreira 228 4050‐313 Porto Portugal Correspondence: Susana Coimbra and Alice Santos‐Silva. E‐mails: ssn.coimbra@gmail.com; assilva@ff.up.pt Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 174, Issue 2, 1 February 2016, Pages 414–416, https://doi.org/10.1111/bjd.14013 Published: 01 February 2016
Clinical study of personalized therapeutics based on genomic/proteomic profiling
Authors: John Nemunaitis, Neil Senzer, Jerry Shen, Phillip Maples, Donald Rao, Alex Tong, Padmasini Kumar, Joe Kuhn, Yu-An Zhang, Jian Liao, Iya Khalil, Colin Hill, Adi Gazdar
Journal: Clinical Cancer Research (2006)

A118   Our therapeutic strategy is to identify signature molecular components comprising key, highly linked, functional nodes of dominant or co-dominant oncogenic pathways. Correlative genomic and proteomic profiling of laser microdissected tissue using cDNA microarray and 2-dimensional Difference Gel Electrophoresis coupled with mass-spectrometry (MS) was used  the bedside to detect differential expression between malignant and 9normal9 tissue. Ten cancer patients (5 melanoma; 2 breast; 1 lymphoma; 1 non-small-cell lung cancer; and 1 colon cancer) are undergoing analysis. Results of target prioritization are complete in patient 1 (melanoma) who demonstrated 45, 16 significantly, up-regulated proteins (≥2 fold) in malignant compared to non-malignant tissue. Six key signature proteins were chosen based on (1) analysis of functions and processes associated with cancer growth and robustness as defined by Hanahan and Weinberg, H&W (self sufficiency, immortality, immune escape, apoptosis, replication, angiogenesis, and invasion), (2) conservation of coupled DNA in eukaryotic completed genomes, and (3) coupled upregulation of mRNA and protein. Western blot analysis with known protein antibodies was used to confirm MS results and identify similar levels of protein expression in selected NCI 60 cell lines and patient malignant tumor samples at 2 different time points of disease from 2 different disease sites.Using our systems biology construct, these 6 proteins underwent gene expression analysis and pathway modeling to determine inter- and intra-pathway connectivity to proteins involved with functions identified by H&W identified involving the 6 key proteins. First order protein-protein interaction connectivity is shown below.GNB2L1, STMN1, and SDCBP are highly connected and are proposed as high priority targets of patient 1 (melanoma) for therapeutic modification testing. SiRNA and shRNA knockdown to validate phenotype and genotype effect  in vitro  and  in vivo  is under way. Vehicles to be tested for clinical delivery have completed toxicology. Compassionate treatment of all 10 patients, once individual priority targets are identified, using delivery-vectored single- and multiplexed-shRNA[s] will provide 9proof of principle9 in establishing the clinical feasibility of personalized therapeutics using genomic/proteomic profiling.